LEXINGTON, Mass., Nov. 7, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting and participation in an analyst-moderated Q&A panel at Cowen's 2nd Annual IO NEXT Summit. Curis' poster presentations will take place on Friday, Nov. 9, with a poster from collaborator Aurigene on Saturday, Nov. 10, at Hall E of the Walter E. Washington Convention Center in Washington, D.C. The Cowen 2nd Annual IO NEXT Summit will take place at the Marriott Marquis in Washington, D.C. featuring a discussion with Jim Dentzer, President and CEO, and Dr. Robert Martell, Head of Research and Development, in an analyst-hosted fireside chat.
In three posters at the SITC conference, Curis will present evidence supporting the presence of high VISTA expression on tumor cells, preclinical data supporting VISTA's ability to independently suppress T cell responses, and Phase 1 clinical trial data of CA-170 in patients with advanced tumors and lymphomas. In addition, Curis collaborator Aurigene will present a poster detailing key findings from its ongoing Phase 2 trial of CA-170 in patients with advanced solid tumors and Hodgkin lymphoma who are immunotherapy treatment-naïve.
Details of these presentations are as follows:
Cowen IO NEXT Summit | |
Date/Time: | Friday, Nov. 09, 11:50 AM – 12:10 PM EST |
Presenters: | Jim Dentzer, President and Chief Executive Officer Robert Martell, M.D., Ph.D., Head of Research and Development |
Location: | Marriot Marquis Washington, DC |
Society for Immunotherapy of Cancer 33rd Annual Meeting | |
CA-170 Poster Presentations from Curis: | |
Date/Time: | Friday, Nov. 9, 12:45 PM – 2:15 PM, 6:30 PM – 8:00 PM EST |
Location: | Hall E, Walter E. Washington Convention Center |
Abstract Number: | P135 |
Presentation Title: | Integrative genomic and proteomic analysis identifies cancer subtypes and signaling networks associated with aberrant tumor expression of VISTA |
Abstract Number: | P139 |
Presentation Title: | Pharmacodynamic effects of CA-170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell activation (VISTA) and PDL1 |
Abstract Number: | P341 |
Presentation Title: | Phase 1 study of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting VISTA and PDL1, in patients with advanced solid tumors or lymphomas |
CA-170 Poster Presentation from Aurigene: | ||
Date/Time: | Saturday, Nov. 10, 12:20 PM – 1:50 PM, 7:00 PM – 8:30 PM EST | |
Location: | Hall E, Walter E. Washington Convention Center | |
Abstract Number: | P714 | |
Presentation Title: | Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients with advanced solid tumor and Hodgkin lymphoma | |
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
SOURCE Curis, Inc.
